Beirne Wealth Consulting Services LLC reduced its position in DURECT Co. (NASDAQ:DRRX – Free Report) by 13.4% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 325,875 shares of the specialty pharmaceutical company’s stock after selling 50,501 shares during the quarter. Beirne Wealth Consulting Services LLC’s holdings in DURECT were worth $244,000 at the end of the most recent reporting period.
Separately, Geode Capital Management LLC boosted its holdings in shares of DURECT by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock valued at $429,000 after purchasing an additional 14,658 shares in the last quarter. 28.03% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on DRRX. StockNews.com assumed coverage on DURECT in a research report on Saturday. They set a “sell” rating for the company. HC Wainwright restated a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th.
DURECT Price Performance
NASDAQ DRRX opened at $0.77 on Wednesday. DURECT Co. has a twelve month low of $0.70 and a twelve month high of $1.88. The business’s fifty day moving average is $0.83 and its 200 day moving average is $1.12. The company has a market cap of $23.87 million, a price-to-earnings ratio of -1.26 and a beta of 0.91.
DURECT Profile
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
Read More
- Five stocks we like better than DURECT
- Manufacturing Stocks Investing
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- Why Are These Companies Considered Blue Chips?
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- Want to Profit on the Downtrend? Downtrends, Explained.
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Want to see what other hedge funds are holding DRRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DURECT Co. (NASDAQ:DRRX – Free Report).
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.
